Indexed on: 04 Mar '17Published on: 04 Mar '17Published in: International Journal of Cardiology
Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy.
Indexed on: 16 Aug '17
Published on: 16 Aug '17 in Clinical toxicology (Philadelphia, Pa.)